Midostaurin Maintenance After Midostaurin Plus Chemotherapy in FLT3-Mutated AML: Post Hoc Analysis in RATIFY

Slideset - No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research